Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI's lead program targets Gaucher-related neurodegeneration, Parkinson's disease and other synucleinopathies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/12/14 | $4,800,000 | Seed |
Atlas Venture Hatteras Venture Partners Orion Equity Partners Partners Innovation Fund Roche Venture Fund | undisclosed |
| 02/03/15 | $20,000,000 | Series A |
Atlas Venture Bob Carpenter Hatteras Venture Partners Henri Termeer Orion Equity Partners Partners Innovation Fund Roche Venture Fund | undisclosed |
